In the treatment of fulminant pulmonary hypertension, general basic therapy is very important, with oxygen therapy, diuretics, digoxin and anticoagulants depending on the condition. Calcium antagonists such as nifedipine and diltiazem are available for those who are suitable for calcium antagonists on cardiac catheterization. Drugs directly targeting pulmonary hypertension currently available in the Chinese market include the following, which can be used in one or a combination depending on the condition. 1, Prostacyclin class: Iloprost (Vantave) 10-20g, inhaled, 6-9 times a day. 2.Endothelin receptor antagonist: bosentan (allcolic) 125mg, orally, twice daily and 62.5mg, orally, twice daily during the first 4 weeks. Use of bosentan requires monitoring of liver function once a month. With Anrisentan (vancomycin), there are fewer adverse liver function reactions. 3. Type 5 phosphodiesterase inhibitors: Sildenafil 20-25mg, orally, 3 times daily. Vardenafil 5mg, orally, twice daily. Studies have proven that the selection of drugs that directly target pulmonary hypertension can effectively improve the prognosis of idiopathic pulmonary hypertension. Because of the high cost of drugs for pulmonary hypertension, Vantanavir and Bosentan currently have a charitable supply program. If there are other causes of pulmonary hypertension, it is also necessary to actively manage the co-morbidities. 4. Treatment of pulmonary hypertension: A stepwise treatment plan based on cardiac function classification and acute vascular response test. If the acute vascular response test is positive, general treatment such as oral calcium channel blocker, oxygen, anticoagulation and function improvement can be given. In addition to general treatment, those with a negative vascular response test are treated separately according to functional class. Endothelin receptor antagonists such as bosentan or anlisentan, or phosphodiesterase 5-inhibitors such as sildenafil can be given in class II; endothelin receptor antagonists, phosphodiesterase 5-inhibitors or prostacyclin and its analogues in class III; prostacyclin and its analogues or endothelin receptor antagonists, phosphodiesterase 5-inhibitors should be applied intravenously for a long time in class IV. Combination therapy should be given if necessary. If the condition does not improve or worsens, surgical treatment is indicated.